Enrolling
CTNPT 047: Letermovir in ART-treated HIV-infected persons
Influence of a 3-month letermovir treatment on gut inflammation in ART-treated HIV-infected persons in an open labelled controlled randomized study
Learn MoreEnrolling
Influence of a 3-month letermovir treatment on gut inflammation in ART-treated HIV-infected persons in an open labelled controlled randomized study
Learn MoreOngoing
Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People with HIV
Learn MoreReporting
A proof-of-concept study to assess the effect of recombinant human growth hormone on the size of the replication-competent viral reservoir in HIV-infected individuals on suppressive ART
Learn MoreReporting
Impact of HIV infection and antiretroviral therapy on mucosal and systemic memory CD4 T cells
Learn MoreResults
A randomized, double blind, phase IIB study testing the efficacy and safety of AGS-004 on host control of HIV replication during analytical treatment interruption: Trial results
Learn MoreReporting
A study of host and viral factors associated with disease progression in long term HIV infected subjects
Learn MoreResults
Chloroquine as a modulator of T cell immune activation to improve CD4 recovery in HIV-infected participants receiving antiretroviral therapy: A proof-of-concept study
Learn MoreResults
A phase II study testing the activity and safety of AGS-004 as an immunotherapeutic in successfully ART-treated subjects infected with HIV-1 in combination with ART followed by ART interruption: Trial results
Learn MoreResults
A pilot study (Phase I/II) testing the immunologic activity and safety of AGS-004, an autologous HIV immunotherapeutic, in HIV-infected adults on HAART: Trial results
Learn More